<unk> , sold under the brand name Trodelvy, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer. The most common side effects include nausea, neutropenia, diarrhea, fatigue, anemia, vomiting, alopecia (hair loss), constipation, decreased appetite, rash and abdominal pain.<unk>  has a boxed warning about the risk of severe neutropenia (abnormally low levels of white blood cells) and severe diarrhea.<unk>  may cause harm to a developing fetus or newborn baby. Women are advised not to breastfeed while on<unk>  and one month after the last dose is administered. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) consider it to be a first-in-class medication.<unk>  was approved for medical use in the European Union in November 2021.
Sacituzumab govitecan
Enfortumab vedotin
Tisotumab vedotin
Tralokinumab
Bezlotoxumab
Ustekinumab
Alirocumab
Lanadelumab